Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Chemotherapy ; 68(3): 131-137, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36549287

RESUMEN

BACKGROUND: Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory (R/R) to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors [CPI]) showed interesting results and were used as bridge therapies to allotransplant. AIM: The aim of this retrospective study in Lazio region was to evaluate the impact of these new therapies on outcome after allogeneic hematopoietic stem cell transplantation (allo-SCT) in comparison with standard chemotherapies used in the past. METHODS: We selected all consecutive patients with diagnosis of HL transplanted in four hematology transplant units, and we collected data obtained from patients' records concerning all the treatments before allo-SCT. RESULTS: A total of 56 patients were enrolled in this study. All patients underwent allo-SCT for R/R HL. Seventeen patients (30%) received chemotherapy prior to allo-SCT (group B); they were treated between 2008 and 2015; and 39 patients (70%) received brentuximab vedotin (BV), CPI, or both before allo-SCT as a bridge to transplant (group A); they were treated between 2012 and 2020. Twenty-five patients were treated with BV alone, 2 with CPI alone, and 12 first with BV and then with CPI. No patient received concomitant BV and CPI. At 5 years from allo-SCT, overall survival (OS) was 59% and progression-free survival (PFS) was 65%. No statistical differences in OS or PFS were observed between patients in groups A and B. Relapse was significantly associated with a lower survival. The only factor associated with a reduced risk of relapse was development of any grade acute graft versus host disease (GVHD) (p > 0.02). CONCLUSIONS: This regional real-world experience shows the changes that have taken place in the last 10 years in R/R HL using new drugs to render a patient eligible for allo-SCT. This strategy appears to guarantee an impressive disease control with an increased risk of complications, for example, aGVHD, that appear to nullify this advantage at least in part.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Enfermedad de Hodgkin , Humanos , Enfermedad de Hodgkin/tratamiento farmacológico , Terapia Recuperativa/métodos , Estudios Retrospectivos , Trasplante Homólogo/efectos adversos , Recurrencia Local de Neoplasia , Brentuximab Vedotina/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/efectos adversos
2.
Eur J Cancer Care (Engl) ; 29(1): e13174, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31571303

RESUMEN

OBJECTIVE: To describe a population of patients referred for fertility preservation (FP), how to efficiently provide FP care, and how FP care changed over time. METHODS: This longitudinal observational study enrolled 281 female cancer patients referred between 2013 and 2016 to the non-profit organisation Gemme Dormienti ONLUS (GD) for FP care. All patients underwent the same battery of instrumental and laboratory diagnostic tests. GnRHa therapy was started at least seven days before CTh treatment. RESULTS: From 2013 to 2016, we observed a progressive increase in the number of patients referred for FP care. Out of 251 eligible patients, 135 patients were treated with GnRHa only, and 72 patients underwent GnRHa therapy and cryopreservation. The median time from GD referral to oocyte and ovarian tissue cryopreservation was 11 and 5 days respectively. Tissue cryopreservation requests increased during our study period (from four cases in 2013 to 17 cases in 2016). During follow-up, 17ß-estradiol and FSH levels were significantly increased (p < .0001), and AMH levels were significantly decreased (p < .0001). CONCLUSION: The rapid increase in the number of patients who requested FP care and in the complexity of FP procedures overtime reflects the need to improve quality of life for cancer patients.


Asunto(s)
Antineoplásicos/efectos adversos , Preservación de la Fertilidad/métodos , Hormona Liberadora de Gonadotropina/agonistas , Infertilidad Femenina/prevención & control , Insuficiencia Ovárica Primaria/prevención & control , Adolescente , Adulto , Hormona Antimülleriana/sangre , Consejo , Criopreservación , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Infertilidad Femenina/inducido químicamente , Estudios Longitudinales , Hormona Luteinizante/sangre , Recuperación del Oocito , Oocitos , Folículo Ovárico , Reserva Ovárica , Ovario , Inducción de la Ovulación , Prioridad del Paciente , Insuficiencia Ovárica Primaria/inducido químicamente , Progesterona/sangre , Derivación y Consulta , Adulto Joven
3.
Clin Case Rep ; 8(8): 1353-1356, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32884752

RESUMEN

Occasionally, non-Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T-cell NHL with both nodal and extranodal involvement. Brentuximab vedotin could be an effective choice in treating metachronous T-cell NHL.

4.
Case Rep Hematol ; 2019: 9651207, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31637066

RESUMEN

Primary cutaneous anaplastic large cell lymphoma is a CD-30 positive lymphoproliferative disorder with good prognosis, usually treated with radiation therapy and surgery. Head, neck, and extremities are the most frequently involved sites. In this paper, we describe an unusual case of oral localization, recurring after skin-involving radiotherapy, successfully treated with sixteen cycles of brentuximab vedotin. This could be a more effective approach with a less detrimental toll for treating these rare disorders.

5.
Clin Case Rep ; 6(10): 1958-1960, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30349706

RESUMEN

We report on a case of Sweet's syndrome associated with multiple myeloma, as harbinger for disease relapse.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA